Common questions about Accofil (FAQ)
Q: What is the active ingredient in Accofil?
The active ingredient in this medicine is filgrastim. According to official product information, filgrastim is classified as a recombinant human granulocyte colony-stimulating factor (r-HuG-CSF), a protein that helps stimulate the production of white blood cells.
Q: What is the substance 'sorbitol' in Accofil and why is it listed as a warning?
Accofil contains the excipient sorbitol, which the body can convert into fructose. Official warnings state that the medicine is subject to a contraindication for individuals with hereditary fructose intolerance (HFI), meaning its use is excluded.
Q: What is the concern about using Accofil in patients with a sickle cell condition?
Regulatory documents advise extreme caution when Accofil is used in patients with a sickle cell disease or trait. Regulatory documents state there have been reports of precipitating a potentially fatal sickle cell crisis in this population.
Q: What is 'Capillary Leak Syndrome' and what are its symptoms?
Capillary Leak Syndrome (CLS) is listed in regulatory documents as a rare but serious side effect of filgrastim products. Reported symptoms have included rapid swelling, significant weight gain, dizziness, fainting, shortness of breath, and feeling very tired or weak.
Q: How long after starting the injections should a person expect the bone pain to begin?
Official information indicates that the onset of bone pain is often linked to the drug's activity in the body. The pain is typically reported in the period immediately before the expected rise in the neutrophil count, which typically occurs in the first one to two days after treatment initiation.
Q: Why is bone pain or musculoskeletal pain such a common side effect of Accofil?
The drug’s mechanism involves accelerating the production and release of neutrophils from the bone marrow. This increased cell activity and expansion within the bone marrow space is understood to be the physiological cause of the reported musculoskeletal pain.
Q: What conditions, other than cancer, is Accofil used for?
Official indications for Accofil include the treatment of severe, persistent low neutrophil counts (neutropenia) in people with advanced HIV infection. It is also indicated for the process of mobilization of peripheral blood progenitor cells (PBPC) for transplantation procedures.
Q: Does Accofil have a specific warning for people who have a latex allergy?
Yes, regulatory documentation confirms this warning. The needle cover of the Accofil pre-filled syringe contains dry natural rubber, which is a derivative of latex and may cause allergic reactions in individuals sensitive to latex.
Q: What general warnings are associated with Accofil use during pregnancy or while breastfeeding?
Accofil is not generally recommended during pregnancy. For breastfeeding, the risk to the breast-fed child cannot be excluded, and official guidance indicates a decision must be made to either discontinue the drug or discontinue breastfeeding.
Q: What general methods are studied for managing bone pain from filgrastim products?
While specific, tailored advice is reserved for the prescribing clinician, official patient information notes that the musculoskeletal pain can be managed with common pain relievers. These include non-opioid analgesics such as acetaminophen (paracetamol) or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Q: Why is the Accofil syringe labeled for single use only?
Official product information states that the syringe is intended for single use only because the solution does not contain any preservative. Official information cautions that reuse carries a possible risk of microbial contamination.
Q: Can Accofil be mixed with other solutions for administration?
When Accofil is administered intravenously, regulatory information specifies that it should be diluted only in 5% glucose solution. Official regulatory documentation states that it should be diluted only in 5% glucose solution for intravenous administration.
Q: What is 'loss of response' and why does it sometimes occur with filgrastim treatment?
Regulatory documentation notes that a loss of response—meaning the drug stops having the intended effect—may occur, although this is uncommon. The loss of response is often linked to the development of neutralising antibodies against filgrastim in the patient’s system.
Q: Does Accofil have potential effects on a patient's hair or weight?
According to the official safety profile, hair loss or thinning of the hair (alopecia) is noted as a common side effect of filgrastim products. Additionally, weight loss is listed as an adverse reaction in clinical data.
Q: What is the significance of the spleen in relation to Accofil treatment?
The drug's activity can cause an enlargement of the spleen (splenomegaly) and, rarely, a serious condition called splenic rupture. Official documentation notes that pain in the left upper abdomen or at the tip of the left shoulder may be a sign of a splenic issue.
Q: What symptoms might suggest inflammation of the aorta (aortitis)?
Inflammation of the aorta (aortitis) has been reported rarely with filgrastim use. Reported symptoms have included fever, general feeling of being unwell (malaise), back pain, and abdominal pain.
Q: Are there differences in the type of needles or syringes used for Accofil compared to other filgrastim products?
Official product presentations describe Accofil as a solution in a pre-filled glass syringe. A specific feature is the inclusion of a needle safety guard, which is a design element that regulatory documentation indicates may differ from its reference product.
